| abstract |
REFERS TO COMPOUNDS DERIVED FROM PHENYLAMIDE OR PYRIDYLAMIDE OF FORMULA (I) WHERE A1 IS CR12 O N; A2 IS CR13 O N, WHERE R12 AND R13 ARE EACH H, ALKYL (C1-C7), HALOGEN, CN, AMONG OTHERS; R1 AND R2 ARE EACH H, ALKYL (C1-C7), CN, AMONG OTHERS; R3 IS H, (C1-C7) ALKYL, (C1-C7) ALCOXY, AMONG OTHERS; R4 IS METHYL, ETHYL, ISOPROPYL, AMONG OTHERS; B1 IS NO CR19; B2 IS N OR CR20, WHERE R19 AND R20 ARE EACH H, HALOGEN, ALCOXY (C1-C7), CN, AMONG OTHERS; R5 AND R6 ARE EACH H, HALOGEN, ALKYL (C1-C7), HALOGEN-ALCOXY (C1-C7), AMONG OTHERS; R7, R8, R9, R10 AND R11 ARE EACH H, ALCOXY (C1-C7), HYDROXY-ALKENYL (C3-C7), PHENYL, AMONG OTHERS. PREFERRED COMPOUNDS ARE: (3,4-DIHYDRO-2H-QUINOLIN-1-IL) - [2- (3-TRIFLUORMETHYL-PHENOXY) -PYRIDIN-3-IL] -METHANONE; [2- (2-CHLORO-PHENOXY) -PYRIDIN-3-IL] - (3,4-DIHYDRO-2H-QUINOLIN-1-IL) -METHANONE; [2- (3-CHLORO-PHENOXY) -PYRIDIN-3-IL] - (3,4-DIHYDRO-2H-QUINOLIN-1-IL) -METHANONE; AMONG OTHERS. IT ALSO REFERS TO A PREPARATION PROCEDURE AND A PHARMACEUTICAL COMPOSITION. THESE COMPOUNDS ARE GPBAR1 AGONISTS, BEING USEFUL IN THE TREATMENT OF DIABETES, OBESITY, METABOLIC SYNDROME, MYOCARDIAL INFARCTION |